Additional Italian Government Covid Recovery Loan
14 October 2021
Directa Plus plc
("Directa Plus" or the "Company")
Additional Italian Government Covid-19 Recovery Loan
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that its Italian subsidiary, Directa Plus S.p.A., has qualified for an additional €0.5m loan under the Italian Government's Covid-19 Recovery Plan. These funds follow the receipt of the €0.7m loan announced on 2 August 2021.
Directa Plus took advantage of the low-cost liquidity offered by the Italian Government in order to accelerate its strategic programme.
The new loan is being provided by Banca Popolare di Sondrio, a major Italian bank. It has a term of 6 years, a variable interest rate of 1.5% +EURIBOR 3M and is 80 per cent. guaranteed by the Italian Government.
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus said: "Directa Plus will leverage on these additional funds offered at low cost by the Italian Government to accelerate its strategic programme and continuing growth."
For further information please visit http://www.directa-plus.com/ or contact:
Directa Plus plc | +39 02 36714458 |
Giulio Cesareo, CEO Giorgio Bonfanti, CFO | |
Cenkos Securities plc (Nominated Adviser and Joint Broker) | +44 131 220 6939 |
Neil McDonald Adam Rae |
|
|
|
Singer Capital Markets (Joint Broker) | +44 20 7496 3069 |
Rick Thompson Phil Davies |
|
|
|
Tavistock (Financial PR and IR) | +44 20 7920 3150 |
Simon Hudson Heather Armstrong |
|
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+® products) and, more recently, lithium-sulphur batteries. In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+® products. All our products are hypoallergenic, non-toxic and sustainably produced.
-ends-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.